N-环庚基-6-甲基-4-氧代吡啶并[1,2-a]嘧啶-3-甲酰胺 | 125055-64-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 中文名称: N-环庚基-6-甲基-4-氧代吡啶并[1,2-a]嘧啶-3-甲酰胺
• 中文别名: N-环庚基-6-甲基-4-羰基-4H-吡啶并[1,2-a]嘧啶-3-甲酰胺
• 英文名称: N-cycloheptyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide
• 英文别名: 4H-Pyrido(1,2-a)pyrimidine-3-carboxamide, N-cycloheptyl-6-methyl-4-oxo-；N-cycloheptyl-6-methyl-4-oxopyrido[1,2-a]pyrimidine-3-carboxamide
• CAS: 125055-64-3
• 化学式: C₁₇H₂₁N₃O₂
• 分子量: 299.373
• InChiKey: XIKVBHWOSOPFKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  61.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-甲基-4-氧代-4H-吡啶并[1,2-a]嘧啶-3-羧酸 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 1.17h， 生成 N-环庚基-6-甲基-4-氧代吡啶并[1,2-a]嘧啶-3-甲酰胺
  参考文献：
  名称：

  Hermecz, Istvan; Vasvari-Debreczy, Lelle; Horvath, Agnes, ACH - Models in Chemistry, 1998, vol. 135, # 4, p. 515 - 528

  摘要：

  DOI：

文献信息

• Pyridopyrimidine derivatives useful in treatment of ulcers
  申请人：Chinoin Gyogyszer- es Vegyeszeti Termekek Gyar Rt.

  公开号：US05158951A1

  公开（公告）日：1992-10-27

  The present invention relates to novel 4-oxo-4H-pyrido[1,2-a]pyrimidine -3-carbonamide derivatives of the general formula (I) and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) ##STR1## wherein: R stands for a C.sub.1-12 alkyl group optionally substituted by a C.sub.1-4 alkoxycarbonyl group; a C.sub.3-9 cycloalkyl, adamantyl or optionally substituted phenyl group; R.sup.1 means hydrogen or a C.sub.1-4 alkyl group; or R and R.sup.1 together form a --(CH.sub.2).sub.n -- chain, wherein n is 4, 5 or 6; R.sup.2 stands for hydrogen, a C.sub.1-4 alkyl group or halogen; R.sup.3 repesents hydrogen or a C.sub.1-4 alkyl group; and m is 0 or 1. The compounds of the general formula (I) possess a gastroprotective effect and are useful for the prevention and therapy of ulcers of the stomach and the small intestine.

  本发明涉及一种新的4-氧代-4H-吡啶并[1,2-a]嘧啶-3-羰胺衍生物，其通式为(I)，以及其酸盐，含有它们的药物组合物和其制备方法。在通式(I)中：其中：R代表一个C.sub.1-12烷基基团，该基团可选择地被C.sub.1-4烷氧羰基基团取代；C.sub.3-9环烷基、脱氢脂环基或可选择地取代的苯基；R.sup.1代表氢或C.sub.1-4烷基基团；或R和R.sup.1一起形成一个--(CH.sub.2).sub.n--链，其中n为4、5或6；R.sup.2代表氢、C.sub.1-4烷基基团或卤素；R.sup.3代表氢或C.sub.1-4烷基基团；m为0或1。通式(I)的化合物具有胃保护作用，对预防和治疗胃和小肠溃疡有用。
• [EN] THIAZOLO(3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY<br/>[FR] THIAZOLO(3,2-A)PYRIMIDINONE ET AUTRES COMPOSÉS HÉTÉROBICYCLIQUES DE PYRIMIDINONE POUR UTILISATION À DES FINS THÉRAPEUTIQUES
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2017040879A1

  公开（公告）日：2017-03-09

  The invention provides heterobicyclic pyrimidinone compounds such as thiazolo[3,2-a]pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary heterobicyclic pyrimidinone compounds described herein include 5-oxo- 2,3-dihydro-5H-hiazolo[3,2-a]pyrimidine-6-carboxarnide compounds.

  该发明提供了异双环嘧啶酮化合物，例如噻唑并[3,2-a]嘧啶酮化合物，含有这种化合物的组合物，医疗工具包，以及使用这种化合物和组合物治疗医学疾病的方法，例如高雪氏病、帕金森病、路易体病、痴呆症或多系统萎缩症。本文描述的示例异双环嘧啶酮化合物包括5-氧代-2,3-二氢-5H-噻唑并[3,2-a]嘧啶-6-羧酰胺化合物。
• Pyridopyrimidine derivatives, pharmaceutical compositions containing
  申请人：Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt.

  公开号：US05252572A1

  公开（公告）日：1993-10-12

  The present invention relates to novel 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide derivatives of the general formula (I) and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) ##STR1## R stands for a C.sub.1-12 alkyl group optionally substituted by a C.sub.1-4 alkoxycarbonyl group; a C.sub.3-9 cycloalkyl, adamantyl or optionally substituted phenyl group; R.sup.1 means hydrogen or a C.sub.1-4 alkyl group; or R and R.sup.1 together form a --(CH.sub.2).sub.n -- chain, wherein n is 4, 5 or 6; R.sup.2 stands for hydrogen, a C.sub.1-4 alkyl group or halogen; R.sup.3 represents hydrogen or a C.sub.1-4 alkyl group; and m is 0 or 1. The compounds of the general formula (I) possess a gastroprotective effect and are useful for the prevention and therapy of ulcers of the stomach and the small intestine.

  本发明涉及一种新型的4-氧代-4H-吡啶[1,2-a]嘧啶-3-羧酰胺衍生物及其酸盐，药物组合物以及它们的制备方法。在通式(I)中，R代表C.sub.1-12烷基，可选地被C.sub.1-4烷氧羰基基团取代；C.sub.3-9环烷基，金刚烷基或可选地被取代的苯基基团；R.sup.1代表氢或C.sub.1-4烷基；或R和R.sup.1一起形成--(CH.sub.2).sub.n--链，其中n为4、5或6；R.sup.2代表氢，C.sub.1-4烷基或卤素；R.sup.3代表氢或C.sub.1-4烷基；m为0或1。通式(I)化合物具有胃黏膜保护作用，可用于预防和治疗胃和小肠溃疡。
• THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY
  申请人：Lysosomal Therapeutics Inc.

  公开号：US20190112316A1

  公开（公告）日：2019-04-18

  The invention provides heterobicyclic pyrimidinone compounds such as thiazolo[3,2-a]pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary heterobicyclic pyrimidinone compounds described herein include 5-oxo-2,3-dihydro-5H-hiazolo[3,2-a]pyrimidine-6-carboxamide compounds.
• US5158951A
  申请人：——

  公开号：US5158951A

  公开（公告）日：1992-10-27